[Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)]

Gynecol Obstet Fertil Senol. 2019 Feb;47(2):111-119. doi: 10.1016/j.gofs.2018.12.011. Epub 2019 Jan 28.
[Article in French]

Abstract

Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A). For BRCA mutated patient, Olaparib is recommended (grade B).

Keywords: Cancer de la trompe; Cancer de l’ovaire; Cancer du péritoine primitif; Chemotherapy; Chimiothérapie; Chirurgie; Fallopian tube cancer; Guidelines; Ovarian cancer; Peritoneal cancer; Recommandations; Surgery.

Publication types

  • Practice Guideline

MeSH terms

  • Age Factors
  • Biomarkers, Tumor / analysis
  • Carcinoma, Ovarian Epithelial / pathology
  • Carcinoma, Ovarian Epithelial / therapy*
  • Chemotherapy, Adjuvant
  • Continuity of Patient Care
  • Fallopian Tube Neoplasms / pathology
  • Fallopian Tube Neoplasms / therapy
  • Female
  • Fertility Preservation
  • France
  • Humans
  • Hyperthermia, Induced
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / therapy
  • Societies, Medical

Substances

  • Biomarkers, Tumor